Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Abuse: White House Expanding Access To Buprenorphine, Naloxone

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS is issuing a proposed rule to increase buprenorphine prescription limit and providing $11m in new funding to states for training and purchase of opioid overdose drug naloxone.

You may also be interested in...



FDA’s Naloxone Product Approval Standards May See Changes

Advisory committees will weigh adequacy of current pharmacokinetic requirements and pediatric dosing for novel formulations of the opioid overdose reversal agent.

Bring Naloxone To Opioid Overdoses: FDA Crowd-Sources Smartphone Apps

FDA announces $40,000 Naloxone App Competition at the start of Prescription Opioid and Heroin Epidemic Awareness Week through Sept. 23, when registration open for the competition, which closes Oct. 7.

Naloxone Costs Could Temper Non-Rx Access Even As Distribution Spreads

CVS in 31 states offers naloxone from pharmacists without a prescription and Walgreens offers it in 14, with plans to more than double the program this year. Whether from pharmacists or OTC, "an affordable price is essential if this is to reach the people who need it," says harm reduction advocate Scott Burris.

Related Content

Topics

UsernamePublicRestriction

Register

PS079260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel